A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

NCT01712217 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer(NSCLC)

Interventions

DRUG: AT13387
DRUG: Crizotinib

Sponsor

Astex Pharmaceuticals, Inc.